Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 9Terminated 4Recruiting 3Withdrawn 2Unknown 2Active not recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 12Thoracic 9Gastrointestinal 7Tumor-Agnostic 4Other hematologic neoplasm 2CNS 2Plasma cell 1Myeloid 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Classical hematology 1Breast 1

Conditions

Neoplasms 3Neoplasm Metastasis 1

Interventions

Gemcitabine 13pembrolizumab 12Capecitabine 9Irinotecan 8Erlotinib Hydrochloride 8Carboplatin 8Blood Specimen Collection 8Nivolumab 7Docetaxel 7Cisplatin 7Cetuximab 7Paclitaxel 6Everolimus 6130-nm albumin-bound paclitaxel 6vadimezan 5Magnetic Resonance Spectroscopy 5Fluorouracil 5Cyclophosphamide 5trametinib 4Leucovorin 4Lapatinib 4Ipilimumab 4Bevacizumab 4Albumin-Bound Paclitaxel 4temsirolimus 3atezolizumab 3abemaciclib 3Trastuzumab 3Radiotherapy 3Radiation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × trametinib × Tumor-Agnostic × Clear all
NCT05071183 2024-04-02

A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

Turning Point Therapeutics, Inc.

Phase 1/2 Terminated
9 enrolled 17 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT04801966 2023-05-10

TAILOR

Peter MacCallum Cancer Centre, Australia

Phase NA Terminated
3 enrolled
Tumor-Agnostic

Neoplasms

NCT01376310 2019-02-19

GSK1120212 Rollover Study

Novartis

Phase 2 Terminated
159 enrolled 9 charts
Tumor-Agnostic

Neoplasms

NCT01248858 2017-05-09

Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors.

GlaxoSmithKline

Phase 1 Terminated
69 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡